

**State of Oklahoma
Oklahoma Health Care Authority
Epcclusa® (Sofosbuvir/Velpatasvir) Initiation Prior Authorization Form**

Member Name: _____ **Date of Birth:** _____ **Member ID#:** _____
Pharmacy NPI: _____ **Pharmacy Phone:** _____ **Pharmacy Fax:** _____
Pharmacy Name: _____ **Pharmacist Name:** _____
Prescriber NPI: _____ **Prescriber Name:** _____ **Specialty:** _____
Prescriber Phone: _____ **Prescriber Fax:** _____ **Drug Name:** _____
NDC: _____ **Start Date:** _____

Clinical Information

1. HCV Genotype (including subtype if applicable): _____ Date Determined: _____
 2. METAVIR Equivalent Fibrosis Stage: _____ Testing Type: _____
Date Fibrosis Stage Determined: _____
 3. Pre-treatment viral load in the last 12 months: _____ Date Taken: _____
For METAVIR score of <F1, 2nd test must confirm chronic HCV diagnosis at least 6 months after 1st test.
Prior pre-treatment viral load or antibody test: _____ Date Taken: _____
 4. Does member have decompensated hepatic disease (CTP class B or C)? Yes ___ No ___
 5. Is the member currently on hospice or does the member have a limited life expectancy (less than 12 months) that cannot be remediated by treating HCV? Yes ___ No ___
 6. Has the member been evaluated by a gastroenterologist, infectious disease specialist, or a transplant specialist within the past 3 months? Yes ___ No ___
 7. If yes, please include name of specialist recommending hepatitis C treatment: _____
 8. Has the member been previously treated for hepatitis C? Yes ___ No ___
 9. If yes, please indicate previous treatment regimen and reason for failure (relapser, null-responder, partial responder): _____
 10. Please indicate requested regimen below:
 - Epcclusa® 400mg/100mg daily x 84 days (12 weeks)
 - Epcclusa® 400mg/100mg daily with weight-based ribavirin x 84 days (12 weeks)
 - Other: _____
 11. Has the member signed the intent to treat contract***? Yes ___ No ___ ***Required for processing of request*
 12. Has the member been counseled on the harms of illicit IV drug use and alcohol use and agreed to not use illicit IV drugs or alcohol while on or after they finish hepatitis C treatment? Yes ___ No ___
 13. Has the member initiated immunization with the hepatitis A and B vaccines? Yes ___ No ___
 14. For women of childbearing potential (and male patients with female partners of childbearing potential):
 - Patient is not pregnant (or a male with a pregnant female partner) and not planning to become pregnant during treatment
 - Agreement that partners will use 2 forms of effective non-hormonal contraception during treatment (and for 6 months after therapy completion for those on ribavirin). Please list non-hormonal birth control options discussed with member _____
 15. Is the member taking any of the following medications: H2-receptor antagonists at doses greater than 40mg famotidine equivalent, amiodarone, omeprazole or other proton pump inhibitors, topotecan, rifampin, rifabutin, rifapentine, carbamazepine, eslicarbazepine, phenytoin, phenobarbital, oxcarbazepine, efavirenz, tenofovir disoproxil fumarate, tipranavir/ritonavir, St. John's wort, or rosuvastatin doses exceeding 10mg? Yes ___ No ___
 16. If member is using antacids have they agreed to separate antacid and Epcclusa® administration by 4 hours? Yes ___ No ___ NA ___
 17. Have all other clinically significant issues been addressed prior to starting therapy? Yes ___ No ___
- This patient is in need of additional support. I recommend this patient be followed by an OHCA Care Management Nurse.

Members must be adherent for continued approval. Treatment gaps of therapy longer than 3 days will result in denial of payment for subsequent requests for continued therapy. Refills must be prior authorized.

Prescriber Signature: _____ **Date:** _____
 Has the member been counseled on appropriate use of Epcclusa® therapy? Yes ___ No ___
Pharmacist Signature: _____ **Date:** _____

Please do not send in chart notes. Failure to complete this form in full will result in processing delays. By signature, the prescriber or pharmacist confirms the above information is accurate.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
 Pharmacy Management Consultants
 Product Based Prior Authorization Unit
 Fax: 1-800-224-4014
 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.